Prognostic utility of human complement factor H related protein test (the BTA stat®Test)

Abstract

The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com

Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer

“…BTA-TRAK™ and BTA-STAT™ are dosages of the Bladder tumor antigen (BTA), which is the human complement factor H-related protein (hCFHrp). hCFHrp plays a major role in alternative pathway regulator factor H. This protein has played a role in the carcinogenesis by giving a selective growth advantage and an escape to the host immune system [ 17 , 18 ]. BTA-TRAK is a urine ELISA test and BTA-STAT™ is a quantitative point-of-care test.…”

Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data

“…In addition, CFH has been suggested as a marker in lung adenocarcinoma 44 , where shorter survival time of patients with adenocarcinoma was associated with increased CFH staining. Data from the TCGA cohort suggest that increased mRNA levels of CFH are significantly related to poor prognosis in kidney carcinoma 45 and urine levels of a closely related protein CFHR1 were negatively related to bladder cancer survival 46 . To our knowledge, negative relation of CFH protein to survival in metastatic melanoma tissue has not been reported.…”

Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement

“…hCFHrp is produced by Bca tumour cells, but it is not detected in healthy bladder tissue and is thought to be involved in allowing the tumour cells to avoid detection by the immune system by downregulating the alternative complement pathway (ACP) [37]. The ACP is constantly active, continually monitoring all cell surfaces it encounters.…”